(Note: This is NOT an IPO. This is a NASDAQ uplisting from the OTC Market Group Inc.’s QB tier, or OTCQB, where the stock trades under the symbol “ATRX.” On Nov. 30, 2022, the last reported sales price of our common stock on the OTCQB was $0.64 per share. We intend to apply to have our common stock and warrants listed on The Nasdaq Capital Market. Adhera Therapeutics, Inc. filed the S-1 for its NASDAQ uplisting and unit public offering on Dec. 2, 2022, but it did NOT disclose proposed symbols for its stock and warrants to be listed on the NASDAQ.)

(Note: This is a unit public offering of stock and warrants that is planned in conjunction with the NASDAQ uplisting. Each unit will consist  of one share of common stock and one warrant to buy one share of common stock.)

(Note: A reverse stock split at a ratio of 1-for-20 became effective on Sept. 30, 2022.)

Adhera is an emerging specialty biotech company that to the extent that resources and opportunities become available, is focused on drug development and commercialization of “small molecule” drugs to treat Parkinson’s disease (PD) and Type 1 diabetes.

A unique feature of Adhera’s accelerated drug development strategy is to identify candidates that have previously been developed for other indications (uses), but where development was discontinued due to lack of efficacy (vs. safety) in these initial indications. The Company secures regulatory approval to commence Phase 2 clinical trials without the need to embark on costly drug discovery or Phase 1 clinical studies.

The Company’s most advanced development programs are MLR-1019, a small molecule drug candidate being developed for Parkinson’s disease, and MLR-1023 being developed to treat Type 1 diabetes. Both drugs are “clinical stage,” i.e., are ready to proceed to Phase 2 clinical trials and  Phase 3 clinical trials within 24 months. Both drugs have been shown to be safe and well tolerated in previous clinical trials (in other indications) or following long-term exposure in large numbers of patients.